Hepatic cytochrome P450 2E1 activity in nondiabetic patients with nonalcoholic steatohepatitis

Naga Chalasani, J. Christopher Gorski, Maleeha S. Asghar, Ali Asghar, Brian Foresman, Stephen D. Hall, David Crabb

Research output: Contribution to journalArticle

245 Citations (Scopus)

Abstract

Cytochrome P450 2E1 (CYP2E1) plays an important role in the pathogenesis of nonalcoholic steatohepatitis (NASH) in animal models, but its role in the pathogenesis of human NASH is unclear. Therefore, we measured hepatic CYP2E1 activity and its correlates in a cohort of nondiabetic patients with NASH (NDN) and controls to explore its role in the pathogenesis of human NASH. Hepatic CYP2E1 activity was assessed using the oral clearance (CLPO) of chlorzoxazone (CHZ) in 20 NDN and 17 age, gender, and body mass index (BMI)-matched controls. The relationship between hepatic CYP2E1 activity and demographic and anthropometric variables; fasting levels of insulin, glucose, lipids, and β-OH butyrate; insulin resistance; and nocturnal hypoxemia was assessed. Furthermore, expression of CYP2E1 in the peripheral lymphocytes was assessed using reverse transcription-poly-merase chain reaction (RT-PCR). The CLPO of CHZ was significantly (P = .03) greater in NDN (41 ± 12 L/h) compared with controls (33 ± 16 L/h). Lymphocyte CYP2E1 messenger RNA was significantly higher in NDN compared with controls (11.5 × 103 ± 10 × 103 vs. 2.6 × 103 ± 1.2 × 103 molecules/μg total RNA, respectively, P < .001). On univariate analysis, BMI, respiratory quotient, high-density lipoprotein, triglycerides, insulin, insulin resistance, hypoxemia, and β-OH butyrate significantly correlated with hepatic CYP2E1 activity. However, on stepwise regression analysis, only nocturnal hypoxemia (r = 0.50, P = .009) and β-OH butyrate (r = 0.37, P = .04) were independent predictors of hepatic CYP2E1 activity. In conclusion, hepatic CYP2E1 activity and lymphocyte CYP2E1 expression are enhanced in NDN. The significant correlations noted between CYP2E1 and hypoxemia and β-OH butyrate suggest that these factors play a role in increased CYP2E1 activity that is seen in patients with NASH.

Original languageEnglish
Pages (from-to)544-550
Number of pages7
JournalHepatology
Volume37
Issue number3
DOIs
StatePublished - Mar 1 2003

Fingerprint

Cytochrome P-450 CYP2E1
Liver
Butyrates
Chlorzoxazone
Lymphocytes
Insulin Resistance
Non-alcoholic Fatty Liver Disease
Body Mass Index
Insulin
HDL Lipoproteins
Reverse Transcription
Fasting
Animal Models

ASJC Scopus subject areas

  • Hepatology

Cite this

Hepatic cytochrome P450 2E1 activity in nondiabetic patients with nonalcoholic steatohepatitis. / Chalasani, Naga; Christopher Gorski, J.; Asghar, Maleeha S.; Asghar, Ali; Foresman, Brian; Hall, Stephen D.; Crabb, David.

In: Hepatology, Vol. 37, No. 3, 01.03.2003, p. 544-550.

Research output: Contribution to journalArticle

Chalasani, N, Christopher Gorski, J, Asghar, MS, Asghar, A, Foresman, B, Hall, SD & Crabb, D 2003, 'Hepatic cytochrome P450 2E1 activity in nondiabetic patients with nonalcoholic steatohepatitis', Hepatology, vol. 37, no. 3, pp. 544-550. https://doi.org/10.1053/jhep.2003.50095
Chalasani, Naga ; Christopher Gorski, J. ; Asghar, Maleeha S. ; Asghar, Ali ; Foresman, Brian ; Hall, Stephen D. ; Crabb, David. / Hepatic cytochrome P450 2E1 activity in nondiabetic patients with nonalcoholic steatohepatitis. In: Hepatology. 2003 ; Vol. 37, No. 3. pp. 544-550.
@article{d1b6da4dcb6b44acaf7f71f9c83e8e76,
title = "Hepatic cytochrome P450 2E1 activity in nondiabetic patients with nonalcoholic steatohepatitis",
abstract = "Cytochrome P450 2E1 (CYP2E1) plays an important role in the pathogenesis of nonalcoholic steatohepatitis (NASH) in animal models, but its role in the pathogenesis of human NASH is unclear. Therefore, we measured hepatic CYP2E1 activity and its correlates in a cohort of nondiabetic patients with NASH (NDN) and controls to explore its role in the pathogenesis of human NASH. Hepatic CYP2E1 activity was assessed using the oral clearance (CLPO) of chlorzoxazone (CHZ) in 20 NDN and 17 age, gender, and body mass index (BMI)-matched controls. The relationship between hepatic CYP2E1 activity and demographic and anthropometric variables; fasting levels of insulin, glucose, lipids, and β-OH butyrate; insulin resistance; and nocturnal hypoxemia was assessed. Furthermore, expression of CYP2E1 in the peripheral lymphocytes was assessed using reverse transcription-poly-merase chain reaction (RT-PCR). The CLPO of CHZ was significantly (P = .03) greater in NDN (41 ± 12 L/h) compared with controls (33 ± 16 L/h). Lymphocyte CYP2E1 messenger RNA was significantly higher in NDN compared with controls (11.5 × 103 ± 10 × 103 vs. 2.6 × 103 ± 1.2 × 103 molecules/μg total RNA, respectively, P < .001). On univariate analysis, BMI, respiratory quotient, high-density lipoprotein, triglycerides, insulin, insulin resistance, hypoxemia, and β-OH butyrate significantly correlated with hepatic CYP2E1 activity. However, on stepwise regression analysis, only nocturnal hypoxemia (r = 0.50, P = .009) and β-OH butyrate (r = 0.37, P = .04) were independent predictors of hepatic CYP2E1 activity. In conclusion, hepatic CYP2E1 activity and lymphocyte CYP2E1 expression are enhanced in NDN. The significant correlations noted between CYP2E1 and hypoxemia and β-OH butyrate suggest that these factors play a role in increased CYP2E1 activity that is seen in patients with NASH.",
author = "Naga Chalasani and {Christopher Gorski}, J. and Asghar, {Maleeha S.} and Ali Asghar and Brian Foresman and Hall, {Stephen D.} and David Crabb",
year = "2003",
month = "3",
day = "1",
doi = "10.1053/jhep.2003.50095",
language = "English",
volume = "37",
pages = "544--550",
journal = "Hepatology",
issn = "0270-9139",
publisher = "John Wiley and Sons Ltd",
number = "3",

}

TY - JOUR

T1 - Hepatic cytochrome P450 2E1 activity in nondiabetic patients with nonalcoholic steatohepatitis

AU - Chalasani, Naga

AU - Christopher Gorski, J.

AU - Asghar, Maleeha S.

AU - Asghar, Ali

AU - Foresman, Brian

AU - Hall, Stephen D.

AU - Crabb, David

PY - 2003/3/1

Y1 - 2003/3/1

N2 - Cytochrome P450 2E1 (CYP2E1) plays an important role in the pathogenesis of nonalcoholic steatohepatitis (NASH) in animal models, but its role in the pathogenesis of human NASH is unclear. Therefore, we measured hepatic CYP2E1 activity and its correlates in a cohort of nondiabetic patients with NASH (NDN) and controls to explore its role in the pathogenesis of human NASH. Hepatic CYP2E1 activity was assessed using the oral clearance (CLPO) of chlorzoxazone (CHZ) in 20 NDN and 17 age, gender, and body mass index (BMI)-matched controls. The relationship between hepatic CYP2E1 activity and demographic and anthropometric variables; fasting levels of insulin, glucose, lipids, and β-OH butyrate; insulin resistance; and nocturnal hypoxemia was assessed. Furthermore, expression of CYP2E1 in the peripheral lymphocytes was assessed using reverse transcription-poly-merase chain reaction (RT-PCR). The CLPO of CHZ was significantly (P = .03) greater in NDN (41 ± 12 L/h) compared with controls (33 ± 16 L/h). Lymphocyte CYP2E1 messenger RNA was significantly higher in NDN compared with controls (11.5 × 103 ± 10 × 103 vs. 2.6 × 103 ± 1.2 × 103 molecules/μg total RNA, respectively, P < .001). On univariate analysis, BMI, respiratory quotient, high-density lipoprotein, triglycerides, insulin, insulin resistance, hypoxemia, and β-OH butyrate significantly correlated with hepatic CYP2E1 activity. However, on stepwise regression analysis, only nocturnal hypoxemia (r = 0.50, P = .009) and β-OH butyrate (r = 0.37, P = .04) were independent predictors of hepatic CYP2E1 activity. In conclusion, hepatic CYP2E1 activity and lymphocyte CYP2E1 expression are enhanced in NDN. The significant correlations noted between CYP2E1 and hypoxemia and β-OH butyrate suggest that these factors play a role in increased CYP2E1 activity that is seen in patients with NASH.

AB - Cytochrome P450 2E1 (CYP2E1) plays an important role in the pathogenesis of nonalcoholic steatohepatitis (NASH) in animal models, but its role in the pathogenesis of human NASH is unclear. Therefore, we measured hepatic CYP2E1 activity and its correlates in a cohort of nondiabetic patients with NASH (NDN) and controls to explore its role in the pathogenesis of human NASH. Hepatic CYP2E1 activity was assessed using the oral clearance (CLPO) of chlorzoxazone (CHZ) in 20 NDN and 17 age, gender, and body mass index (BMI)-matched controls. The relationship between hepatic CYP2E1 activity and demographic and anthropometric variables; fasting levels of insulin, glucose, lipids, and β-OH butyrate; insulin resistance; and nocturnal hypoxemia was assessed. Furthermore, expression of CYP2E1 in the peripheral lymphocytes was assessed using reverse transcription-poly-merase chain reaction (RT-PCR). The CLPO of CHZ was significantly (P = .03) greater in NDN (41 ± 12 L/h) compared with controls (33 ± 16 L/h). Lymphocyte CYP2E1 messenger RNA was significantly higher in NDN compared with controls (11.5 × 103 ± 10 × 103 vs. 2.6 × 103 ± 1.2 × 103 molecules/μg total RNA, respectively, P < .001). On univariate analysis, BMI, respiratory quotient, high-density lipoprotein, triglycerides, insulin, insulin resistance, hypoxemia, and β-OH butyrate significantly correlated with hepatic CYP2E1 activity. However, on stepwise regression analysis, only nocturnal hypoxemia (r = 0.50, P = .009) and β-OH butyrate (r = 0.37, P = .04) were independent predictors of hepatic CYP2E1 activity. In conclusion, hepatic CYP2E1 activity and lymphocyte CYP2E1 expression are enhanced in NDN. The significant correlations noted between CYP2E1 and hypoxemia and β-OH butyrate suggest that these factors play a role in increased CYP2E1 activity that is seen in patients with NASH.

UR - http://www.scopus.com/inward/record.url?scp=0037369729&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037369729&partnerID=8YFLogxK

U2 - 10.1053/jhep.2003.50095

DO - 10.1053/jhep.2003.50095

M3 - Article

VL - 37

SP - 544

EP - 550

JO - Hepatology

JF - Hepatology

SN - 0270-9139

IS - 3

ER -